Fig. 1. Schematic illustration of Jablonski energetic diagram

Fig. 2. GSH-activatable dicyanine photosensitizer DCy7^[39]。(a) GSH-activation mechanism of Dcy7; (b)-(d) UV absorption, fluorescence and ¹O₂ generation of DCy7 treated by GSH

Fig. 3. GSH-activation mechanism of BODIPY derivative for PDT^[40]

Fig. 4. MB and CPT release mechanism of GSH-activatable photosensitizer LMB-S-CPT^[42]

Fig. 5. Activation mechanism of GSH-responsive BODIPY-based photosensitizers^[43]

Fig. 6. Chemical structure and therapeutic mechanism of prodrug B-BDP-CL-CPT^[44]. (a) Chemical structure; (b) therapeutic mechanism

Fig. 7. Activation mechanism of TDBP^[46]

Fig. 8. Activation mechanism and tumor therapy of photosensitizer CyI-DNBS^[47]

Fig. 9. Schematic illustration of GSH activation and phototoxicity of Ru-azo^[48]

Fig. 10. GSH-activation mechanism of photosensitizer NO₂-BDP^[52]

Fig. 11. Activation mechanism of photosensitizer PS-Q^[53]

Fig. 12. Structure and preparation of Ru-based photosensitizer, and schematic diagram of intracellular process of GSH-depletion and enhanced two-photon PDT^[56]

Fig. 13. Synthesis and biological action mechanism of a biodegradable iridium (Ⅲ) coordination polymer^[57]

Fig. 14. Schematic diagram of synthetic route of MSNs-I₂BDP-PEG and its tumor PDT^[58]

Fig. 15. Schematic illustration of aMMTm preparation and combination therapy of PDT and antiangiogenesis^[60]

Fig. 16. Schematic illustration of Mn(Ⅲ)-TCPP MOFs for MRI- and optical imaging-guided PDT by controlled ROS generation and GSH depletion after being unlocked by overexpressed GSH in tumor cells^[61]

Fig. 17. Synthesis of photosensitizer FT@HA NPs and activated combination therapy in vivo^[62]

Fig. 18. Schematic illustration of 3D Cu@COF-TATB for cancer immunotherapy via PDT/CDT-triggered ICD^[63]